智通财经APP讯，医渡科技(02158)发布公告，近期，公司的联属公司天津开心生活科技有限公司中标山东衍渡生物科技有限公司重组人神经生长因子(SMR001)滴眼液III期临床研究项目，项目总金额约为人民币5581.76万元。
作为中国AI医疗变革驱动者，医渡科技秉承“使精准医疗惠及每一个人”的使命，打造专业、高效、精准且普惠的医学人工智能产品与解决方案。基于公司自主研发的核心算法引擎YiduCore，医渡科技构建“数据—算法—场景”飞轮闭环，实现了AI技术的高效率创新、低成本规模化应用，推动智能决策赋能“医—药—险—患者”全产业链生态。
AI医疗的核心是通过提升医学证据质量与生成效率，优化研发、诊断及治疗流程，最终实现更安全、更优质、更可及的医疗服务。医渡科技持续提升医疗服务效率与可及性，让医生拥有更精准高效的决策工具，让药企缩短分子到患者距离，让患者享有更可负担的精准诊断和治疗，让公共系统获得更科学的支撑。医疗AI的价值，体现在对每一个个体生命的尊重与对健康福祉的守护。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.